Literature DB >> 12209502

Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients.

Nicola J Goodson1, Nicola J Wiles, Mark Lunt, Elizabeth M Barrett, Alan J Silman, Deborah P M Symmons.   

Abstract

OBJECTIVE: To determine the degree and causes of any excess mortality observed during the early years of inflammatory polyarthritis (IP).
METHODS: Between 1990 and 1994, a total of 1,236 patients were registered with the Norfolk Arthritis Register, a primary care-based inception cohort. All patients were tracked on the National Health Service Central Register for notification of death. The vital status of each patient was determined as of December 31, 1999. Causes of death were coded according to the International Classification of Diseases, Ninth Revision. Expected death rates were calculated using annual death rates for the Norfolk population. Standardized mortality ratios (SMRs) were calculated for all IP patients and for the subgroups of patients who did and did not satisfy the American College of Rheumatology (ACR) 1987 criteria for rheumatoid arthritis (RA) at baseline, as well as for the subgroups who were and were not rheumatoid factor (RF) positive at baseline.
RESULTS: By December 31, 1999, 160 patients (13%; 79 women and 81 men) had died. The median duration of followup in the entire cohort was 6.9 years. Mortality rates were not significantly increased in the entire group of patients with IP or in the subgroup who met the ACR 1987 criteria for RA at baseline. In contrast, RF-positive patients had an increased rate of death from all causes (SMR in men 1.51, in women 1.41). Cardiovascular disease was the most common cause of death. The majority of the excess mortality in the RF-positive patients could be attributed to cardiovascular causes (SMR in men 1.34, in women 2.02).
CONCLUSION: Excess mortality in the early years of IP is confined to patients who are seropositive for RF. While excess cardiovascular mortality has been described in patients with established RA, this is the first report of premature death from heart disease in the early years of IP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209502     DOI: 10.1002/art.10419

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  119 in total

1.  Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Authors:  Laura R Rekedal; Elena Massarotti; Rajesh Garg; Radhika Bhatia; Timothy Gleeson; Bing Lu; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2010-12

Review 2.  Epidemiology research in rheumatology-progress and pitfalls.

Authors:  Deborah P M Symmons
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

Review 3.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 4.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

5.  What if Derek Willoughby were right? Cyclo-oxygenase is an anti-inflammatory enzyme.

Authors:  D R Blake; N Shenker; H Cohen; C R Stevens
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

6.  Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany: II. The contribution of leflunomide to efficiency.

Authors:  Peter K Schädlich; Henning Zeidler; Angela Zink; Erika Gromnica-Ihle; Matthias Schneider; Christoph Straub; Josef G Brecht; Eduard Huppertz
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Rheumatoid factor positivity increases all-cause and cancer mortality: a cohort study.

Authors:  Joong Kyong Ahn; Jiwon Hwang; Yoosoo Chang; Seungho Ryu
Journal:  Rheumatol Int       Date:  2017-05-17       Impact factor: 2.631

8.  Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study.

Authors:  Joseph J Keller; Jung-Lung Hsu; Shiue-Ming Lin; Chia-Chi Chou; Li-Hsuan Wang; Jui Wang; Chyi-Huey Bai; Hung-Yi Chiou
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

9.  Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

Authors:  Zurab Nadareishvili; Kaleb Michaud; John M Hallenbeck; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-08-15

Review 10.  Biologics and heart failure in rheumatoid arthritis: are we any wiser?

Authors:  Maria I Danila; Nivedita M Patkar; Jeffrey R Curtis; Kenneth G Saag; Gim Gee Teng
Journal:  Curr Opin Rheumatol       Date:  2008-05       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.